Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Multicare Health Systems

Neither a doctor nor a teaching hospital

Research payments

$778,559

46 payments

Through program year 2025, Multicare Health Systems is reported as receiving $778,559 in research payments, across 46 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $7,046 3
2024 Research $7,111 8
2023 Research $11,967 12
2022 Research $669,349 16
2021 Research $63,059 6
2020 Research $20,027 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. GlaxoSmithKline, LLC. $717,903 16 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $22,415 22 payments
  3. OPKO Pharmaceuticals, LLC $20,027 1 payment
  4. Ipsen Bioscience Inc $14,200 5 payments
  5. Sanofi US Services Inc. $3,710 1 payment
  6. AstraZeneca Pharmaceuticals LP $304 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase III, Randomized, Open-Label, Controlled, Multi-Center Study to $713,789 15 payments
  2. A Phase 3, Open-Label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly Mod-4023 Compared to Daily Genotropin Therapy in Pre-Pubertal Children With Growth Hormone Deficiency $20,027 1 payment
  3. RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy $14,200 5 payments
  4. Fine-Real $11,967 12 payments
  5. BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. $10,448 10 payments
  6. A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $4,114 1 payment
  7. A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus $3,710 1 payment
  8. Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab $304 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record